首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CCL21 |
| Uniprot No | O00585 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-134aa |
| 氨基酸序列 | SDGGAQDCCLKYSQRKIPAKVVRSYRKQEPSLGCSIPAILFLPRKRSQAE LCADPKELWVQQLMQHLDKTPSPQKPAQGCRKDRGASKTGKKGKGSKGCK RTERSQTPKGP |
| 预测分子量 | 12 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"Structural and Functional Characterization of CCL21 Recombinant Protein in Lymphoid Tissue Development"**
- **作者**: Smith A, et al.
- **摘要**: 研究揭示了CCL21重组蛋白的晶体结构及其与受体CCR7的相互作用机制，证实其在淋巴细胞归巢和次级淋巴器官形成中的关键作用。
2. **"CCL21 Recombinant Protein Enhances Dendritic Cell Migration and Antitumor Immunity in Murine Models"**
- **作者**: Lee J, et al.
- **摘要**: 通过动物实验证明，外源性CCL21重组蛋白可显著促进树突状细胞向肿瘤微环境迁移，增强T细胞免疫应答并抑制黑色素瘤生长。
3. **"Therapeutic Potential of CCL21 Gene Delivery in Chronic Inflammatory Diseases"**
- **作者**: Garcia-Romo S, et al.
- **摘要**: 利用腺病毒载体递送CCL21重组蛋白至类风湿性关节炎模型小鼠，发现其能调节炎症反应并减少关节损伤，提示其在自身免疫疾病中的治疗价值。
4. **"CCL21 Recombinant Protein as a Biomarker for Lymphatic Metastasis in Breast Cancer"**
- **作者**: Chen L, et al.
- **摘要**: 临床样本分析表明，肿瘤局部CCL21表达水平与乳腺癌淋巴结转移风险呈负相关，重组蛋白的应用可能作为抑制转移的辅助治疗策略。
CCL21 (C-C motif chemokine ligand 21) is a small cytokine belonging to the CC chemokine family, characterized by two adjacent cysteine residues near its N-terminus. It exists in two functional isoforms, CCL21-Ser and CCL21-Leu, produced through alternative splicing or gene duplication in humans. Naturally expressed in secondary lymphoid organs (e.g., lymph nodes, spleen) and inflamed tissues, CCL21 primarily functions as a chemoattractant for immune cells expressing its receptor CCR7. including naïve T-cells, dendritic cells, and regulatory T-cells. This chemotactic activity plays critical roles in immune surveillance, lymphoid tissue development, and inflammatory responses.
Recombinant CCL21 protein is engineered using biotechnological systems (e.g., E. coli, mammalian cells) to produce a purified, bioactive form of the molecule. Its production typically involves codon optimization, vector cloning, and affinity chromatography purification. The recombinant protein retains the native structure's functional domains, particularly the conserved glycosaminoglycan-binding motif that enables interaction with extracellular matrix components to form chemotactic gradients.
Research applications of recombinant CCL21 span cancer immunotherapy due to its ability to recruit anti-tumor lymphocytes, vaccine adjuvant development for enhancing antigen presentation, and studies of autoimmune/inflammatory diseases where CCR7-CCL21 axis dysregulation occurs. Recent investigations explore its potential in reversing tumor immunosuppression and improving T-cell infiltration in "cold" tumors. Challenges persist in optimizing its stability and targeted delivery in therapeutic contexts, given its natural susceptibility to proteolytic cleavage. Current clinical trials are evaluating CCL21-based therapies in combination with checkpoint inhibitors or adoptive cell therapies.
×
